Literature DB >> 28461311

Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.

Bruna G S Torres1, Victória E Helfer1, Priscila M Bernardes1, Alexandre José Macedo1,2, Elisabet I Nielsen3, Lena E Friberg3, Teresa Dalla Costa4.   

Abstract

Biofilm formation plays an important role in the persistence of pulmonary infections, for example, in cystic fibrosis patients. So far, little is known about the antimicrobial lung disposition in biofilm-associated pneumonia. This study aimed to evaluate, by microdialysis, ciprofloxacin (CIP) penetration into the lungs of healthy and Pseudomonas aeruginosa biofilm-infected rats and to develop a comprehensive model to describe the CIP disposition under both conditions. P. aeruginosa was immobilized into alginate beads and intratracheally inoculated 14 days before CIP administration (20 mg/kg of body weight). Plasma and microdialysate were sampled from different animal groups, and the observations were evaluated by noncompartmental analysis (NCA) and population pharmacokinetic (popPK) analysis. The final model that successfully described all data consisted of an arterial and a venous central compartment and two peripheral distribution compartments, and the disposition in the lung was modeled as a two-compartment model structure linked to the venous compartment. Plasma clearance was approximately 32% lower in infected animals, leading to a significantly higher level of plasma CIP exposure (area under the concentration-time curve from time zero to infinity, 27.3 ± 12.1 μg · h/ml and 13.3 ± 3.5 μg · h/ml in infected and healthy rats, respectively). Despite the plasma exposure, infected animals showed a four times lower tissue concentration/plasma concentration ratio (lung penetration factor = 0.44 and 1.69 in infected and healthy rats, respectively), and lung clearance (CLlung) was added to the model for these animals (CLlung = 0.643 liters/h/kg) to explain the lower tissue concentrations. Our results indicate that P. aeruginosa biofilm infection reduces the CIP free interstitial lung concentrations and increases plasma exposure, suggesting that plasma concentrations alone are not a good surrogate of lung concentrations.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; biofilm; ciprofloxacin; microdialysis; pneumonia; population pharmacokinetics

Mesh:

Substances:

Year:  2017        PMID: 28461311      PMCID: PMC5487627          DOI: 10.1128/AAC.02553-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  A physiologically based pharmacokinetic model for capreomycin.

Authors:  B Reisfeld; C P Metzler; M A Lyons; A N Mayeno; E J Brooks; M A Degroote
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 3.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

4.  Simultaneous Semimechanistic Population Analyses of Levofloxacin in Plasma, Lung, and Prostate To Describe the Influence of Efflux Transporters on Drug Distribution following Intravenous and Intratracheal Administration.

Authors:  Estevan Sonego Zimmermann; João Victor Laureano; Camila Neris Dos Santos; Stephan Schmidt; Chakradhar V Lagishetty; Whocely Victor de Castro; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

5.  Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment.

Authors:  María D Macià; José L Pérez; Soeren Molin; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

6.  Bactericidal activity of various antibiotics against biofilm-producing Pseudomonas aeruginosa.

Authors:  A Abdi-Ali; M Mohammadi-Mehr; Y Agha Alaei
Journal:  Int J Antimicrob Agents       Date:  2006-02-03       Impact factor: 5.283

Review 7.  Murine models of acute and chronic lung infection with cystic fibrosis pathogens.

Authors:  Alessandra Bragonzi
Journal:  Int J Med Microbiol       Date:  2010-10-14       Impact factor: 3.473

8.  Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.

Authors:  Felipe K Hurtado; Benjamin Weber; Hartmut Derendorf; Guenther Hochhaus; Teresa Dalla Costa
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

9.  Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration data.

Authors:  David S Burgess; Ronald G Hall
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

10.  Evaluation of gatifloxacin penetration into skeletal muscle and lung by microdialysis in rats.

Authors:  Leandro Tasso; Clarissa C Bettoni; Laura K Oliveira; Teresa Dalla Costa
Journal:  Int J Pharm       Date:  2008-03-04       Impact factor: 5.875

View more
  1 in total

1.  Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic Pseudomonas aeruginosa Lung Infection Based on Preclinical Population Pharmacokinetic Modeling.

Authors:  Bruna Bernar Dias; Fernando Carreño; Victória Etges Helfer; Priscila Martini Bernardi Garzella; Daiane Maria Fonseca de Lima; Fabiano Barreto; Bibiana Verlindo de Araújo; Teresa Dalla Costa
Journal:  Pharmaceutics       Date:  2022-06-11       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.